Description
Due to many new and updated therapeutic options in liver treatments, the American Association for the Study of Liver Diseases has created new guidelines to help the physician identify paths to the best treatment options for the patient. This presentation discusses key updates and clinical implications of non-invasive tests for hepatic fibrosis and steatosis. During this guideline update, participants will be presented with ways to identify the key updates in the guidelines that will impact their practice and discuss the care of patients based on the new guideline recommendations.
Learning Objectives
Upon completion of this course, a participant should be able to:
- Identify the key updates of the guideline that will impact practice
- Discuss the application of the guideline's recommendations to the care of patients.
Faculty and Disclosures:
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the Guidelines Update faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The following financial disclosures are below:
Andrew Keaveny:
Scientific Advisor: Mallincrokdt Pharmaceuticals, Biovie, Inc.
Research Grants: HepQuant LLC, Biovie, Inc. Mallinckrodt Medical, Gabriel House of Care, River 2 Renal Company
Intellectual Property Rights: UpToDate,
Richard Sterling:
Research Grants: Gilead Sciences, Inc., Roche, Abbott, AbbVie, Zydus
Steven Folstein:
Nothing to Disclose
Accreditation Information
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: August 14, 2024 Expiration Date: August 14, 2026
COPYRIGHT: All faculty in this activity have given permission for publication 2024 AASLD.
Privacy Policy